NCT05497310 2022-10-26
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 1/2 Unknown
Clinical Trials
13 trialsNCT05297123 2022-03-28
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
First Affiliated Hospital Xi'an Jiaotong University
Phase 1 Unknown
NCT05175508 2022-01-03
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
The First Affiliated Hospital of Soochow University
Phase 2/3 Unknown
NCT02899169 2021-09-08
APL16
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT05016349 2021-08-23
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
Kafrelsheikh University
Phase 3 Unknown
NCT01064557 2020-10-14
"AIDA" Protocol (LAP 0493)
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase NA Unknown
NCT01064570 2020-10-14
AIDA 2000 Guidelines
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Unknown
NCT01987297 2019-08-19
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Shanghai Jiao Tong University School of Medicine
Phase 4 Unknown
NCT02717884 2018-10-18
TRANSATRA
University Hospital Freiburg
Phase 1/2 Unknown
NCT01226303 2017-01-26
Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 3 Unknown
NCT00002658 2013-12-19
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005825 2013-12-18
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002701 2013-09-20
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Unknown